- | Omalizumab | Mepolizumab | Benralizumab | Dupilumab |
n | 183 | 11 | 22 | 54 |
F:M | 119:64 | 8:3 | 12:10 | 32:22 |
Age Median (IQR) |
35 (28.5-43) | 42 (32-79) | 44.5 (15-64) | 39 (16-78) |
Indications (n) | -Chronic Urticaria (148) | -Asthma (7) | -Asthma (39) | |
-Asthma (31) | -EGPA (3) | Asthma (22) | -Dermatitis (13) | |
EGPA (3) | -Eosinophilic cystitis (1) | -Chronic rhinosinusitis with nasal polyposis (2) | ||
-ABPA (1) | ||||
Mean Dose Frequency (weeks) | 4.4 | 4 | 8 | 2.2 |
Mean Dosage (mg) | 311.1 | 172.7 | 30 | 300 |
Adverse Effects (n) | -Pruritus (2) | |||
-Urticaria (1) | None reported | Migraines (1) | Pruritus + Dizziness (1) | |
-Vasovagal reaction (1) |